FBT - First Trust NYSE Arca Biotech ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
132.78
+0.41 (+0.31%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close132.37
Open134.04
Bid0.00 x 2900
Ask0.00 x 800
Day's Range131.57 - 134.67
52 Week Range120.98 - 159.85
Volume171,990
Avg. Volume405,134
Net Assets2.78B
NAV140.02
PE Ratio (TTM)N/A
Yield0.00%
YTD Return12.43%
Beta (3Y Monthly)1.92
Expense Ratio (net)0.56%
Inception Date2006-06-19
Trade prices are not sourced from all markets
  • Why Exelixis Stock Soared 46% in November
    Market Realist8 days ago

    Why Exelixis Stock Soared 46% in November

    Exelixis stock rose from $13.87 at the close of markets on October 31, 2018, to reach $20.31 at the close of market on November 30, 2018, a ~46% increase over the last month. Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29, 2018. Exelixis stock experienced solid growth after the company released its third-quarter financial results on November 1, 2018.

  • How BioMarin Pharmaceutical’s Financials Look in November
    Market Realist12 days ago

    How BioMarin Pharmaceutical’s Financials Look in November

    BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year, a ~19% YoY increase. BioMarin Pharmaceutical reported net revenues of $391.7 million in the third quarter, which reflected ~17% YoY growth.

  • 7 Biotech ETFs to Consider for 2019
    InvestorPlace21 days ago

    7 Biotech ETFs to Consider for 2019

  • A Look at Exelixis’s Financials in November
    Market Realistlast month

    A Look at Exelixis’s Financials in November

    Exelixis reported revenues of $625.2 million in the first nine months of this year compared to $332.4 million in the same period the prior year. In the third quarter, Exelixis generated revenues of $162.9 million from product sales compared to $96.4 million in the third quarter of 2017, reflecting ~69% YoY growth. Exelixis generated $62.5 million in collaboration revenues in the third quarter compared to $56.1 million in the third quarter of 2017.

  • Analysts Expect Incyte to Report Revenue Growth in Third Quarter
    Market Realist2 months ago

    Analysts Expect Incyte to Report Revenue Growth in Third Quarter

    As discussed earlier, analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018. The below graph compares the revenues of Incyte since the first quarter of 2017 and estimates for the third quarter of 2018. Incyte’s revenue stream includes product sales, royalty revenues, and other revenues from collaborations. Incyte acquired the commercial rights for Iclusig from Ariad Pharmaceuticals in 2016.

  • Alkermes in the Third Quarter: A Performance Overview
    Market Realist2 months ago

    Alkermes in the Third Quarter: A Performance Overview

    Alkermes (ALKS) reported its third-quarter financial results on October 23. It generated net revenues of $248.7 million compared to $217.4 million in the third quarter of 2017. That was a 14% YoY (year-over-year) growth.

  • A Financial Overview of Ionis Pharmaceuticals in October
    Market Realist2 months ago

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated second-quarter revenues of $118.0 million compared to $122.3 million in the second quarter of 2017, which reflected ~15.0% YoY (year-over-year) growth. In the first half, Ionis Pharmaceuticals reported revenues of $262.2 million, compared to $228.1 million in the first half of 2017.

  • Ionis Pharmaceuticals’ Revenue Stream
    Market Realist2 months ago

    Ionis Pharmaceuticals’ Revenue Stream

    Ionis Pharmaceuticals’ (IONS) revenue stream is segregated into two segments: Research and Development revenues from the collaborative agreements with other companies, and Commercial Revenues. Commercial Revenues include licensing and royalty revenues and Spinraza royalties. The chart below compares the revenues for Ionis Pharmaceuticals since the first quarter of 2017.

  • How Vertex Pharmaceuticals Is Positioned Financially
    Market Realist2 months ago

    How Vertex Pharmaceuticals Is Positioned Financially

    In the first half of this year, Vertex Pharmaceuticals’ (VRTX) revenue grew ~40% YoY (year-over-year) to $1.4 billion from $994.6 million. Kalydeco, Orkambi, and Symdeko saw revenue of $253.0 million, $311.0 million, and $186.0 million, respectively, in Q2 2018, compared with $250.0 million, $354.0 million, and $34.0 million, respectively, in Q1 2018. Vertex’s revenue growth could boost the First Trust NYSE Arca Biotechnology Index ETF (FBT), of which Vertex comprises ~3.33%.

  • Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
    Market Realist2 months ago

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).

  • Investor's Business Daily3 months ago

    Top ETFs: First Trust Biotech Beats Larger Rivals

    Smaller is better for First Trust NYSE Arca Biotechnology Index Fund, which has become one of the top ETFs by using a concentrated portfolio.

  • Estimates and Recommendations for Bluebird Bio on September 6
    Market Realist3 months ago

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017. Its EPS is expected to be -$10.83 in 2018. Analysts estimate net adjusted loss of $556.6 million in 2018.

  • How Analysts View BioMarin Pharmaceutical in August
    Market Realist3 months ago

    How Analysts View BioMarin Pharmaceutical in August

    On August 30, BioMarin Pharmaceutical (BMRN) stock closed at $99.26, which is ~7% below its 52-week high of $106.20 on August 2. It hit its 52-week low of $75.81 on April 6. 

  • Incyte’s Revenue Stream in Q2 2018
    Market Realist4 months ago

    Incyte’s Revenue Stream in Q2 2018

    Incyte (INCY) reported revenue of $521.5 million in the second quarter, a 59.7% rise YoY (year-over-year) compared to $326.4 million in the second quarter of 2017.

  • Investor's Business Daily4 months ago

    Smaller Is Better For This Biotech Play Up More Than 20% In 2018

    The ETF is up more than 20% this year, earning a spot on IBD's ETF Leaders screen. It's done that with a portfolio that's concentrated on just 30 holdings.

  • What Do Analysts Expect from Ionis’s Q2 2018 Earnings?
    Market Realist4 months ago

    What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

    Ionis Pharmaceuticals (IONS) is one of the leading RNA-targeted therapeutics companies. The company aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes approved products in collaboration with other pharmaceutical companies. Ionis is set to release its Q2 2018 earnings on August 7. Wall Street analysts estimate a net loss of $0.09 per share on revenues of $135.5 million in the second quarter of 2018.

  • Investopedia4 months ago

    Adding Biotech ETFs to Your Portfolio

    As the name suggests, the biotechnology sector combines elements of biology with the development and manufacturing of products and business ventures. Both of these components have experienced unbelievable advances in recent decades, making the biotechnology area an exciting one for investors. Best of all, biotechnology's impact covers an ever-expanding range of tangential fields and areas, including medicine, pharmaceuticals, the environment, food, genetics and much more.

  • Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates
    Market Realist4 months ago

    Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates

    Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018, compared to estimates for EPS of $0.34 on revenues of $473.8 million.

  • Bluebird Bio’s Q2 2018 Earnings: Analysts’ Estimates
    Market Realist4 months ago

    Bluebird Bio’s Q2 2018 Earnings: Analysts’ Estimates

    Clinical-stage biotechnology company Bluebird Bio (BLUE) is set to release its Q2 2018 results tomorrow. The company has research and development collaborations with Celgene (CELG), TC BioPharm, Lonza, MediGene, and Apceth Biopharma.

  • Business Wire5 months ago

    Chile’s Pension Risk Rating Commission Approves Sale of Additional First Trust ETF

    First Trust Advisors L.P. (“First Trust”), a global ETF provider and asset manager, announced that Chilean pension funds investment risk rating commission, La Comisión Clasificadora de Riesgo (CCR), has approved an additional First Trust exchange-traded fund (ETF) for sale to Chilean pension funds, known as la Asociación de Administradoras de Fondos de Pensiones (AFPs). According to Chile’s pension plan investment guidelines, before an ETF can be purchased in a pension fund, it must be approved by the CCR.

  • 5 Safe and Sound ETF Strategies for 2H
    InvestorPlace5 months ago

    5 Safe and Sound ETF Strategies for 2H

    After a bumpy ride in the first half of the year, global stocks are bouncing back, with iShares MSCI ACWI Index Fund (NASDAQ:ACWI), which targets the global stock market, up 1% last week. The U.S. stocks, as indicated by SPDR S&P 500 ETF (NYSEARCA:SPY), which tracks the S&P 500 index, is up 1.5% to start the second half versus 0.6% gain for Vanguard FTSE All-World ex-US ETF (NYSEARCA:VEU), which targets the international equity market excluding the United States.Source: Investment Zen via Flickr (Modified)

  • What Investors Need to Know about Biotech ETFs
    Zacks5 months ago

    What Investors Need to Know about Biotech ETFs

    Smaller biotech stocks are outperforming this year; learn more about biotech ETFs best positioned to benefit

  • ETF Trends5 months ago

    Biotech ETFs Climb on Biogen’s Promising Clinical Trial

    Biotech ETFs rallied Friday after Biogen (NasdaqGS: BIIB) announced successful results from its Alzheimer’s drug trial. On Friday, large-cap biotechnology sector ETFs lead the charge. The iShares Nasdaq ...

  • Incyte’s Collaborations and Developments in Q1 2018
    Market Realist6 months ago

    Incyte’s Collaborations and Developments in Q1 2018

    Incyte (INCY) has a well-established distribution network in the United States and sells its products Jakafi and Iclusig in the United States through its own network.

  • What Analysts Think about Ionis
    Market Realist7 months ago

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.